HighTower Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-6
Closed -$9K 3487
2021
Q4
$9K Buy
+6
New +$530 ﹤0.01% 3160
2019
Q3
Sell
-200
Closed -$3K 2448
2019
Q2
$3K Buy
+200
New +$20.2K ﹤0.01% 2339
2018
Q2
Sell
-1,000
Closed -$10K 2288
2018
Q1
$10K Buy
1,000
+500
+100% +$24.4K ﹤0.01% 2085
2017
Q4
$4K Buy
+500
New +$26.7K ﹤0.01% 2214
2017
Q3
Sell
-500
Closed -$2K 2266
2017
Q2
$2K Buy
+500
New +$15.4K ﹤0.01% 2177
2017
Q1
Sell
-1,000
Closed -$2K 2110
2016
Q4
$2K Buy
+1,000
New +$16.1K ﹤0.01% 1907
2014
Q3
Sell
-20,000
Closed -$14K 1576
2014
Q2
$14K Sell
20,000
-60,000
-75% -$826K ﹤0.01% 1579
2014
Q1
$24K Buy
80,000
+45,000
+129% +$608K ﹤0.01% 1475
2013
Q4
$60K Buy
+35,000
New +$402K ﹤0.01% 1409

Other funds holding EXAS

HighTower Advisors's EXAS Position: Q1 2026 in Review

HighTower Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 1,227,761 shares — an estimated $125M sold.

HighTower Advisors first reported a position in EXAS in Q2 2013 and held it in 51 quarters. The position peaked at $125M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • HighTower Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 1,227,761 Exact Sciences shares in Q1 2026, an estimated $125M.
  • HighTower Advisors first reported a position in Exact Sciences in Q2 2013 and held it in 51 quarters.
  • HighTower Advisors's Exact Sciences position peaked at $125M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.